oregovomab: Clinical Trials

5 trials of oregovomab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 1 active not recruiting, 1 unknown. 5 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Terminated 3, Active not recruiting 1, Unknown 1
Phase 24Terminated 2, Active not recruiting 1, Unknown 1

Follow oregovomab: new trials by email Literature Review of oregovomab trials Research Report on oregovomab

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Oregovomab, Bevacizumab, Paclitaxel - Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III
Phase 1 / Phase 2Active not recruitingCanariaBio Inc.542021-03-172026-04-06
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
Oregovomab, Nivolumab, Chemotherapy - Epithelial Ovarian Cancer
Phase 1 / Phase 2UnknownNational Cancer Centre, Singapore312020-10-072021-12-01
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
Oregovomab, Poly ICLC - Cancer of Ovary, Neoplasms, Ovarian
Phase 1TerminatedCanariaBio Inc.102017-05-302020-12-22
Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
Nivolumab, Oregovomab - Epithelial Ovarian Cancer
Phase 1 / Phase 2TerminatedNational Cancer Centre, Singapore132017-02-222022-06-13
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
oregovomab - Ovarian Neoplasms
Phase 1 / Phase 2TerminatedUnither Pharmaceuticals242002-03-012007-12-18

Conditions studied

Carcinoma, Ovarian Epithelial (3)  ·  Ovarian Neoplasms (3)

Sponsors

CanariaBio Inc. (2)  ·  National Cancer Centre, Singapore (2)  ·  Unither Pharmaceuticals (1)

Countries

Singapore (2)  ·  United States (2)  ·  South Korea (1)

Top investigators

Christopher Nicodemus, MD FACP (1)  ·  Dr Jung KH, MD (1)  ·  Jack Chan (1)  ·  Jack Chan, MD (1)